Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL708799 | 1.00 | CYP1A2 (0.62) | CYP1A2CYP2D6NAAATRPA1MIF | |
| SCHEMBL706895 | 1.00 | CYP1A2 (0.62) | CYP1A2CYP2D6NAAATRPA1MIF | |
| SCHEMBL707888 | 1.00 | CYP1A2 (0.62) | CYP1A2CYP2D6NAAATRPA1MIF | |
| SCHEMBL9812561 | 0.92 | NAAA (0.56) | CYP1A2CYP2D6NAAA | |
| SCHEMBL9812470 | 0.92 | NAAA (0.56) | CYP1A2CYP2D6NAAA | |
| Hydrochloric Acid SCHEMBL28124752 | 0.90 | NAAA (0.54) | CYP1A2CYP2D6NAAA | |
| SCHEMBL18133507 | 0.89 | CYP1A2 (0.58) | CYP1A2CYP2D6NAAA | |
| SCHEMBL5183227 | 0.86 | — | — | |
| SCHEMBL7837960 | 0.84 | CYP1A2 (0.84) | CYP1A2CYP2D6NAAA | |
| Hydrochloric Acid SCHEMBL7284486 | 0.82 | CYP1A2 (0.81) | CYP1A2CYP2D6NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289901-A2 | THERMOFORMED ARTICLE | Novamont S.p.A. (IT) | 2023-12-13 | — | — | EP | claimed |
| EP-4032953-B1 | THERMOFORMED ARTICLE | NOVAMONT SPA (IT) | 2023-12-06 | — | — | EP | claimed |
| US-11767425-B2 | Polymer composition for the manufacture of thermoformed articles | NOVAMONT S.P.A. (IT) | 2023-09-26 | — | — | US | claimed |
| US-20220213233-A1 | CROSSLINKED POLYMER OF FUNCTIONALIZED HYALURONIC ACID AND ITS USE IN THE TREATMENT OF INFLAMMATORY STATES | JOINTHERAPEUTICS S.R.L. (IT) | 2022-07-07 | — | — | US | claimed |
| EP-3956367-A1 | CROSSLINKED POLYMER OF FUNCTIONALIZED HYALURONIC ACID AND ITS USE IN THE TREATMENT OF INFLAMMATORY STATES | Jointherapeutics S.r.l. (IT) | 2022-02-23 | — | — | EP | claimed |
| US-20200369871-A1 | POLYMER COMPOSITION FOR THE MANUFACTURE OF THERMOFORMED ARTICLES | NOVAMONT S.P.A. (IT) | 2020-11-26 | — | — | US | claimed |
| WO-2020212920-A1 | CROSSLINKED POLYMER OF FUNCTIONALIZED HYALURONIC ACID AND ITS USE IN THE TREATMENT OF INFLAMMATORY STATES | JOINTHERAPEUTICS SRL (IT) | 2020-10-22 | — | — | WO | claimed |
| US-10774214-B2 | Polymer composition for the manufacture of thermoformed articles | NOVAMONT S.P.A. (IT) | 2020-09-15 | — | — | US | claimed |
| US-20180223095-A1 | POLYMER COMPOSITION FOR THE MANUFACTURE OF THERMOFORMED ARTICLES | NOVAMONT S.P.A. (IT) | 2018-08-09 | — | — | US | claimed |
| EP-3328941-A1 | POLYMER COMPOSITION FOR THE MANUFACTURE OF THERMOFORMED ARTICLES | Novamont S.p.A. (IT) | 2018-06-06 | — | — | EP | claimed |
| EP-1699500-B1 | CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION | ANIKA THERAPEUTICS INC (US) | 2018-02-21 | — | — | EP | claimed |
| WO-2017021338-A1 | POLYMER COMPOSITION FOR THE MANUFACTURE OF THERMOFORMED ARTICLES | NOVAMONT S.P.A. (IT) | 2017-02-09 | — | — | WO | claimed |
| EP-1305064-B1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS INC (US) | 2008-04-23 | — | — | EP | claimed |
| EP-1699500-A1 | CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION | Anika Therapeutics Inc. (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005067994-A1 | CROSSLINKED HYALURONIC ACID COMPOSITIONS FOR TISSUE AUGMENTATION | ANIKA THERAPEUTICS, INC. (US) | 2005-07-28 | — | — | WO | claimed |
| US-20050136122-A1 | Crosslinked hyaluronic acid compositions for tissue augmentation | ANIKA THERAPEUTICS, INC. (US) | 2005-06-23 | — | — | US | claimed |
| EP-1305064-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | Anika Therapeutics Inc. (US) | 2003-05-02 | — | — | EP | claimed |
| US-6548081-B2 | Hyaluronic acid derivative is an N-acylurea that results from crosslinking hyaluronic acid with a multifunctional carbodiimide. reducing post-operative adhesion of tissues. | ANIKA THERAPEUTICS, INC. | 2003-04-15 | — | — | US | claimed |
| US-20020071855-A1 | Bioabsorbable composites of derivatized hyaluronic acid and other biodegradable, biocompatible polymers | ANIKA THERAPEUTICS, INC | 2002-06-13 | — | — | US | claimed |
| WO-2002009792-A1 | BIOABSORBABLE COMPOSITES OF DERIVATIZED HYALURONIC ACID | ANIKA THERAPEUTICS, INC. (US) | 2002-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050136122-A1 | Crosslinked hyaluronic acid compositions for tissue augmentation | H1-0, H1-2, CD44 | CYP1A2 2058/4885CYP2D6 1753/4885NAAA 473/4885 |
| US-20220213233-A1 | CROSSLINKED POLYMER OF FUNCTIONALIZED HYALURONIC ACID AND ITS USE IN THE TREATMENT OF INFLAMMATORY STATES | LGALS1, LGALS2, LGALS3 | CYP1A2 3351/4885CYP2D6 3410/4885NAAA 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.